Enveric Biosciences, Inc. (NASDAQ:ENVB) Sees Large Decrease in Short Interest

Enveric Biosciences, Inc. (NASDAQ:ENVB) was the target of a large decline in short interest in the month of December. As of December 31st, there was short interest totalling 68,100 shares, a decline of 56.7% from the December 15th total of 157,200 shares. Based on an average daily volume of 667,800 shares, the days-to-cover ratio is presently 0.1 days. Approximately 0.7% of the company’s shares are short sold.

Enveric Biosciences Trading Down 2.2 %

Shares of ENVB stock traded down $0.01 during midday trading on Tuesday, reaching $0.37. 229,408 shares of the stock were exchanged, compared to its average volume of 1,157,639. Enveric Biosciences has a 1 year low of $0.30 and a 1 year high of $2.92. The firm has a market cap of $3.73 million, a PE ratio of -0.14 and a beta of 0.62. The company’s 50 day moving average is $0.37 and its two-hundred day moving average is $0.45.

About Enveric Biosciences

Enveric Biosciences, Inc, a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health.